Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma presents Livatag Phase II follow up results
Livatag is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. It was granted an orphan drug status in Europe and in the US. The
Livatag is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. It was granted an orphan drug status in Europe and in the US. The
Each retail package of Sucanon contains 60 tablets and is the equivalent of a one-month patient supply. Pre-clinical and clinical studies of Sucanon showed that Sucanon and other
PRT062607 is a novel, oral Spleen Tyrosine Kinase (Syk)-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosis, and certain cancers,
FDA alleged in letters to drug companies that their products were ‘unapproved new drugs’ which can no longer be marketed legally in the US for safety problems associated
With this acquisition, Laboratoires Thea is planning to strengthen its geographical presence by establishing new affiliates in countries where the company’s products were either sold through distributors or
GBR401 has been developed completely in-house by Glenmark‘s Biologics Research Centre located in Switzerland, using an advanced technology. GBR 401 targets lymphomas, leukemia’s of B-cell origin and inflammatory
to-BBB is planning to initiate the Phase I/II clinical trial in a few months at three academic hospitals in the Netherlands led by neuro-oncology experts of the Antoni
ANAVEX 2-73 is a new class of oral, disease-modifying drug being studied to potentially treat alzheimer’s disease itself, versus treating its symptoms. The Phase 1 study will evaluate
BioMAP offers insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds. The Patent no.
The study, a 48-week, global, double-blind, randomized, placebo-controlled trial, involved nearly 300 previously untreated patients infected with the most common form of hepatitis C virus (HCV), the genotype